<DOC>
	<DOCNO>NCT00498797</DOCNO>
	<brief_summary>The purpose study determine whether treatment Zactima ( vandetanib ) combination Docetaxel Prednisolone effective standard Docetaxel Prednisolone alone prostate cancer , patient Hormone refractory prostate cancer previously receive chemotherapy .</brief_summary>
	<brief_title>E3-Hormone Refractory Prostrate Cancer Taxotere Combination</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Metastatic hormone refractory prostate cancer define patient evidence progression disease spite castrate level testosterone indicate rise level PSA No previous chemotherapy although patient receive estramustine enter study provide estramustine stop 3 week dose study drug screen PSA value &gt; 20ng/ml . must confirm two separate measurement least 2 week apart Treatment within 4 week randomization and/or whilst study , treatment following : 1 ) nonapproved experimental drug , 2 ) treatment drug similar mechanism action ZD6474 concurrent treatment anticancer agent , othr docetaxel prednisolone define protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>zactima</keyword>
	<keyword>vandetanib</keyword>
	<keyword>metastatic</keyword>
</DOC>